The two Copenhagen Prospective Studies on Asthma in Childhood (COPSAC) cohorts, COPSAC₂₀₀₀ and COPSAC₂₀₁₀, comprise 1100 children which have been followed extensively since pregnancy and birth. The cohorts focus on deep phenotyping through repeated objective examinations, early life multi-compartment biobanking and standardized diagnosis and treatment of asthma, allergy and eczema, as well as longitudinal monitoring of growth, obesity, metabolism, neurodevelopment, and neuropsychiatric endpoints.

The cohorts were founded by Hans Bisgaard, starting more than twenty years ago. The COPSAC team has now grown to more than 50 people dedicated to clinically based translational research to improve disease prevention, diagnosis and treatment in children.

In HEDIMED, COPSAC will play an important role based on the deeply characterized clinical cohorts and expertise in both diseases and translational omics analyses for uncovering exposomic determinants and mechanistic mediators of the development of immune-mediated diseases in children.